CheckMate914
Por um escritor misterioso
Descrição
Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
CheckMate914
Toni Choueiri, MD on X: Checkmate-914 (adjuvant nivo/ipi) vs placebo in high-risk Kidney Cancer is out in the @TheLancet: the study is negative with no DFS/OS advantage. 33% disc. for toxicity could
Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC
ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial
A trial of nivolumab with or without ipilimumab after surgery for kidney cancer (CheckMate 914)
Adjuvant Nivolumab/Ipilimumab vs Placebo in Localized Renal Cell Carcinoma - The ASCO Post
A trial of nivolumab with or without ipilimumab after surgery for kidney cancer (CheckMate 914)
ASCO 2020: A Phase III, Randomized, Placebo-Controlled Trial of Nivolumab or Nivolumab plus Ipilimumab in Patients with Localized Renal Cell Carcinoma at High-Risk of Relapse after Radical or Partial Nephrectomy (CheckMate 914)
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma - European Urology
de
por adulto (o preço varia de acordo com o tamanho do grupo)
